|
Name |
Dihydroagarofuran. cis-
|
Molecular Formula | C15H26O | |
IUPAC Name* |
(1S,2R,6R,9R)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodecane
|
|
SMILES |
C[C@@H]1CCC[C@]2([C@]13C[C@@H](CC2)C(O3)(C)C)C
|
|
InChI |
InChI=1S/C15H26O/c1-11-6-5-8-14(4)9-7-12-10-15(11,14)16-13(12,2)3/h11-12H,5-10H2,1-4H3/t11-,12-,14-,15+/m1/s1
|
|
InChIKey |
HVAVUZLEYSAYGE-GBOPCIDUSA-N
|
|
Synonyms |
cis-Dihydroagarofuran; Dihydroagarofuran. cis-; 7QLI5HGG0I; 150652-94-1; 2H-3,9a-Methano-1-benzoxepin, octahydro-2,2,5a,9-tetramethyl-, (3R,5aR,9R,9aS)-; (1S,2R,6R,9R)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodecane; UNII-7QLI5HGG0I; CHEBI:166672; 2H-3,9a-Methano-1-benzoxepin, octahydro-2,2,5a,9-tetramethyl-, (3R-(3alpha,5abeta,9alpha,9aalpha))-; Q27268716; 2H-3,9A-METHANO-1-BENZOXEPIN, OCTAHYDRO-2,2,5A,9-TETRAMETHYL-, (3R-(3.ALPHA.,5A.BETA.,9.ALPHA.,9A.ALPHA.))-
|
|
CAS | 150652-94-1 | |
PubChem CID | 90478975 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 222.37 | ALogp: | 3.9 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 9.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 16 | QED Weighted: | 0.575 |
Caco-2 Permeability: | -4.693 | MDCK Permeability: | 0.00001990 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.009 |
30% Bioavailability (F30%): | 0.161 |
Blood-Brain-Barrier Penetration (BBB): | 0.11 | Plasma Protein Binding (PPB): | 97.17% |
Volume Distribution (VD): | 1.454 | Fu: | 2.41% |
CYP1A2-inhibitor: | 0.141 | CYP1A2-substrate: | 0.724 |
CYP2C19-inhibitor: | 0.373 | CYP2C19-substrate: | 0.946 |
CYP2C9-inhibitor: | 0.31 | CYP2C9-substrate: | 0.47 |
CYP2D6-inhibitor: | 0.045 | CYP2D6-substrate: | 0.776 |
CYP3A4-inhibitor: | 0.266 | CYP3A4-substrate: | 0.446 |
Clearance (CL): | 8.415 | Half-life (T1/2): | 0.149 |
hERG Blockers: | 0.083 | Human Hepatotoxicity (H-HT): | 0.824 |
Drug-inuced Liver Injury (DILI): | 0.135 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.044 | Maximum Recommended Daily Dose: | 0.361 |
Skin Sensitization: | 0.592 | Carcinogencity: | 0.155 |
Eye Corrosion: | 0.928 | Eye Irritation: | 0.978 |
Respiratory Toxicity: | 0.953 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001810 | 1.000 | D0V8HA | 0.288 | ||||
ENC002337 | 0.544 | D0H1QY | 0.281 | ||||
ENC002074 | 0.492 | D0U3GL | 0.280 | ||||
ENC005519 | 0.451 | D0L2LS | 0.253 | ||||
ENC000085 | 0.451 | D0Z1XD | 0.250 | ||||
ENC001322 | 0.403 | D0Q6NZ | 0.250 | ||||
ENC002262 | 0.381 | D08QKJ | 0.244 | ||||
ENC001893 | 0.381 | D0I2SD | 0.244 | ||||
ENC001172 | 0.381 | D09NNA | 0.234 | ||||
ENC000592 | 0.379 | D03XOC | 0.233 |